Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 9, Pages e74820
Publisher
Public Library of Science (PLoS)
Online
2013-09-04
DOI
10.1371/journal.pone.0074820
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
- (2012) M. S. de Souza et al. JOURNAL OF IMMUNOLOGY
- Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
- (2012) D. C. Montefiori et al. JOURNAL OF INFECTIOUS DISEASES
- ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases
- (2012) A. Baz Morelli et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
- (2011) Theo Nicholaou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells
- (2011) P. Duewell et al. JOURNAL OF IMMUNOLOGY
- Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
- (2011) Punnee Pitisuttithum et al. PLoS One
- Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers
- (2010) Debbie Drane et al. Human vaccines & immunotherapeutics
- ISCOMATRIX™ vaccines: Safety in human clinical studies
- (2010) Andrew McKenzie et al. Human vaccines & immunotherapeutics
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity
- (2010) Michael Vaine et al. VACCINE
- Mechanism of action of clinically approved adjuvants
- (2009) Bart N Lambrecht et al. CURRENT OPINION IN IMMUNOLOGY
- A Randomized, Placebo-Controlled, Dose-Escalation Study to Determine the Safety, Tolerability, and Immunogenicity of an HPV-16 Therapeutic Vaccine in HIV-Positive Participants With Oncogenic HPV Infection of the Anus
- (2009) Jonathan S Anderson et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
- (2009) Supachai Rerks-Ngarm et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vasculitis of small blood vessels - some riddles about IgA and about the complexity of transmigration
- (2008) Cord Sunderkötter EXPERIMENTAL DERMATOLOGY
- Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration
- (2008) A. Bansal et al. JOURNAL OF VIROLOGY
- Lipid A and liposomes containing lipid A as antigens and adjuvants
- (2008) Carl R. Alving et al. VACCINE
- Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers
- (2008) Shixia Wang et al. VACCINE
- The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers
- (2008) Jeffrey S. Kennedy et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now